Paper38612640
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
Chrysavgis LG and 5 others. Int J Mol Sci, 2024. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. Papers, record 38612640. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38612640
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Fatty Liver | Major topic |
| Liver Diseases | Major topic |
| Metabolic Diseases | Major topic |
| Humans | |
| Gastric Inhibitory Polypeptide | |
| Glucagon-Like Peptide 1 | |
| Incretins | |
| Receptors, G-Protein-Coupled | |
| Receptors, Glucagon |
Source PubMed
References143
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32952876 | Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. | World J Hepatol | 2020 | https://conductscience.org/library/papers/32952876 | PubMed |
| 2 | 18292967 | Glucagon receptors. | Cell Mol Life Sci | 2008 | https://conductscience.org/library/papers/18292967 | PubMed |
| 3 | 37758044 | Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. | Am Heart J | 2024 | https://conductscience.org/library/papers/37758044 | PubMed |
| 4 | 32696080 | NAFLD and cardiovascular diseases: a clinical review. | Clin Res Cardiol | 2021 | https://conductscience.org/library/papers/32696080 | PubMed |
| 5 | 30359962 | Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | Pharmacol Res | 2018 | https://conductscience.org/library/papers/30359962 | PubMed |
| 6 | 37379656 | Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice. | EBioMedicine | 2023 | https://conductscience.org/library/papers/37379656 | PubMed |
| 7 | 34570916 | Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. | Aliment Pharmacol Ther | 2021 | https://conductscience.org/library/papers/34570916 | PubMed |
| 8 | 32059982 | NAFLD as a driver of chronic kidney disease. | J Hepatol | 2020 | https://conductscience.org/library/papers/32059982 | PubMed |
| 9 | 25053587 | Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. | Diabetes | 2015 | https://conductscience.org/library/papers/25053587 | PubMed |
| 10 | 37364790 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | J Hepatol | 2023 | https://conductscience.org/library/papers/37364790 | PubMed |
| 11 | 32196896 | Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. | Diabetes Obes Metab | 2020 | https://conductscience.org/library/papers/32196896 | PubMed |
| 12 | 28648835 | Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. | Diabetes Metab | 2017 | https://conductscience.org/library/papers/28648835 | PubMed |
| 13 | 19141695 | Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. | Am J Clin Nutr | 2009 | https://conductscience.org/library/papers/19141695 | PubMed |
| 14 | 36626630 | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. | Hepatology | 2023 | https://conductscience.org/library/papers/36626630 | PubMed |
| 15 | 32478287 | Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. | Nat Metab | 2020 | https://conductscience.org/library/papers/32478287 | PubMed |
| 16 | 38095657 | Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. | Diabetologia | 2024 | https://conductscience.org/library/papers/38095657 | PubMed |
| 17 | 37103096 | Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis. | In Vivo | 2023 | https://conductscience.org/library/papers/37103096 | PubMed |
| 18 | 31671603 | Glucagon Regulation of Energy Expenditure. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31671603 | PubMed |
| 19 | 18723001 | Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice. | Biochem Biophys Res Commun | 2008 | https://conductscience.org/library/papers/18723001 | PubMed |
| 20 | 37149203 | Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy. | Semin Cancer Biol | 2023 | https://conductscience.org/library/papers/37149203 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42387035 | Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation. | Endocrine | 2026 | https://conductscience.org/library/papers/42387035 | PubMed |
| 42278284 | Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278284 | PubMed |
| 42078303 | Glucagon-Like Peptide-1 Receptor Agonists Reduce Liver Stiffness in a Pediatric Metabolic Dysfunction-Associated Liver Disease Cohort and Normalize Disease-Associated Core Gene Expression in an Experimental Model. | Cureus | 2026 | https://conductscience.org/library/papers/42078303 | PubMed |
| 41715264 | Emerging therapeutic regimens as alternatives to glucocorticoids for severe alcohol-associated hepatitis: a comprehensive review. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/41715264 | PubMed |
| 41465555 | The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465555 | PubMed |
| 41266634 | Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice. | Sci Rep | 2025 | https://conductscience.org/library/papers/41266634 | PubMed |
| 41231418 | AI-Based Models for Risk Prediction in MASLD: A Systematic Review. | Dig Dis Sci | 2026 | https://conductscience.org/library/papers/41231418 | PubMed |
| 40938549 | Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients. | Cardiovasc Drugs Ther | 2026 | https://conductscience.org/library/papers/40938549 | PubMed |
| 40937349 | GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies. | Front Clin Diabetes Healthc | 2025 | https://conductscience.org/library/papers/40937349 | PubMed |
| 40751781 | Sex and gender differences in metabolic dysfunction-associated liver disease. | Indian J Gastroenterol | 2026 | https://conductscience.org/library/papers/40751781 | PubMed |
| 40722592 | Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment? | Biomedicines | 2025 | https://conductscience.org/library/papers/40722592 | PubMed |
| 40391051 | The Therapeutic Effect and Mechanism of Traditional Chinese Medicine in Type 2 Diabetes Mellitus and Its Complications. | Diabetes Metab Syndr Obes | 2025 | https://conductscience.org/library/papers/40391051 | PubMed |
| 39200096 | Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions. | Biomedicines | 2024 | https://conductscience.org/library/papers/39200096 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GCGR | 2642 | PubTator's text mining | https://conductscience.org/library/genes/2642 | NCBI Gene |
| GIP | 2695 | PubTator's text mining | https://conductscience.org/library/genes/2695 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38612640
GET https://conductscience.org/api/papers/v1/38612640/references?page=2